nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—CYP2E1—Dacarbazine—muscle cancer	0.269	0.412	CbGbCtD
Methazolamide—CYP2E1—Etoposide—muscle cancer	0.132	0.202	CbGbCtD
Methazolamide—SLC22A6—Methotrexate—muscle cancer	0.0989	0.151	CbGbCtD
Methazolamide—CYP3A4—Vincristine—muscle cancer	0.0436	0.0667	CbGbCtD
Methazolamide—CYP2D6—Doxorubicin—muscle cancer	0.0429	0.0655	CbGbCtD
Methazolamide—CYP3A4—Etoposide—muscle cancer	0.04	0.0611	CbGbCtD
Methazolamide—CYP3A4—Doxorubicin—muscle cancer	0.0272	0.0417	CbGbCtD
Methazolamide—Hepatic insufficiency—Methotrexate—muscle cancer	0.0167	0.058	CcSEcCtD
Methazolamide—Metabolic acidosis—Etoposide—muscle cancer	0.0109	0.0379	CcSEcCtD
Methazolamide—Bone marrow depression—Vincristine—muscle cancer	0.00787	0.0274	CcSEcCtD
Methazolamide—Aplastic anaemia—Dactinomycin—muscle cancer	0.00558	0.0194	CcSEcCtD
Methazolamide—Tingling sensation—Etoposide—muscle cancer	0.00535	0.0186	CcSEcCtD
Methazolamide—Appetite absent—Methotrexate—muscle cancer	0.00518	0.018	CcSEcCtD
Methazolamide—Urine output increased—Vincristine—muscle cancer	0.0048	0.0167	CcSEcCtD
Methazolamide—Hepatic failure—Dactinomycin—muscle cancer	0.0048	0.0167	CcSEcCtD
Methazolamide—Polyuria—Vincristine—muscle cancer	0.00439	0.0153	CcSEcCtD
Methazolamide—Hepatic failure—Vincristine—muscle cancer	0.00429	0.0149	CcSEcCtD
Methazolamide—CA7—renal system—muscle cancer	0.00389	0.0662	CbGeAlD
Methazolamide—Toxic epidermal necrolysis—Dactinomycin—muscle cancer	0.00388	0.0135	CcSEcCtD
Methazolamide—Bone marrow depression—Methotrexate—muscle cancer	0.00382	0.0133	CcSEcCtD
Methazolamide—Pancytopenia—Dactinomycin—muscle cancer	0.00354	0.0123	CcSEcCtD
Methazolamide—Bone marrow depression—Doxorubicin—muscle cancer	0.0033	0.0115	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.0033	0.0115	CcSEcCtD
Methazolamide—Pancytopenia—Vincristine—muscle cancer	0.00316	0.011	CcSEcCtD
Methazolamide—Agranulocytosis—Dactinomycin—muscle cancer	0.0031	0.0108	CcSEcCtD
Methazolamide—Photosensitivity reaction—Vincristine—muscle cancer	0.00304	0.0106	CcSEcCtD
Methazolamide—CA14—cardiac atrium—muscle cancer	0.0029	0.0494	CbGeAlD
Methazolamide—Erythema multiforme—Dactinomycin—muscle cancer	0.00282	0.00982	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Etoposide—muscle cancer	0.00281	0.00979	CcSEcCtD
Methazolamide—Glycosuria—Doxorubicin—muscle cancer	0.00275	0.00958	CcSEcCtD
Methazolamide—Blood disorder—Doxorubicin—muscle cancer	0.00267	0.0093	CcSEcCtD
Methazolamide—CA9—tendon—muscle cancer	0.00267	0.0454	CbGeAlD
Methazolamide—Pancytopenia—Etoposide—muscle cancer	0.00256	0.00892	CcSEcCtD
Methazolamide—CA14—tendon—muscle cancer	0.00253	0.043	CbGeAlD
Methazolamide—CA12—renal system—muscle cancer	0.00253	0.043	CbGeAlD
Methazolamide—CA6—head—muscle cancer	0.00252	0.0429	CbGeAlD
Methazolamide—Melaena—Methotrexate—muscle cancer	0.00252	0.00876	CcSEcCtD
Methazolamide—Aplastic anaemia—Methotrexate—muscle cancer	0.00242	0.00842	CcSEcCtD
Methazolamide—Ill-defined disorder—Dactinomycin—muscle cancer	0.00241	0.00839	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.00239	0.0083	CcSEcCtD
Methazolamide—Malaise—Dactinomycin—muscle cancer	0.00234	0.00815	CcSEcCtD
Methazolamide—Urine output increased—Methotrexate—muscle cancer	0.00233	0.00811	CcSEcCtD
Methazolamide—Leukopenia—Dactinomycin—muscle cancer	0.00233	0.00809	CcSEcCtD
Methazolamide—Agranulocytosis—Etoposide—muscle cancer	0.00225	0.00781	CcSEcCtD
Methazolamide—CA9—testis—muscle cancer	0.00221	0.0376	CbGeAlD
Methazolamide—Discomfort—Dactinomycin—muscle cancer	0.00219	0.00761	CcSEcCtD
Methazolamide—Melaena—Doxorubicin—muscle cancer	0.00218	0.00758	CcSEcCtD
Methazolamide—Polyuria—Methotrexate—muscle cancer	0.00213	0.00741	CcSEcCtD
Methazolamide—Photosensitivity—Methotrexate—muscle cancer	0.00213	0.00741	CcSEcCtD
Methazolamide—Aplastic anaemia—Doxorubicin—muscle cancer	0.00209	0.00729	CcSEcCtD
Methazolamide—Vertigo—Vincristine—muscle cancer	0.00209	0.00726	CcSEcCtD
Methazolamide—Hepatic failure—Methotrexate—muscle cancer	0.00208	0.00724	CcSEcCtD
Methazolamide—Leukopenia—Vincristine—muscle cancer	0.00208	0.00723	CcSEcCtD
Methazolamide—Erythema multiforme—Etoposide—muscle cancer	0.00204	0.00711	CcSEcCtD
Methazolamide—CA5B—cardiac atrium—muscle cancer	0.00203	0.0345	CbGeAlD
Methazolamide—Anorexia—Dactinomycin—muscle cancer	0.00202	0.00703	CcSEcCtD
Methazolamide—Convulsion—Vincristine—muscle cancer	0.00201	0.007	CcSEcCtD
Methazolamide—CA1—renal system—muscle cancer	0.002	0.034	CbGeAlD
Methazolamide—Anaphylactic shock—Vincristine—muscle cancer	0.00189	0.00659	CcSEcCtD
Methazolamide—Photosensitivity—Doxorubicin—muscle cancer	0.00184	0.00642	CcSEcCtD
Methazolamide—Decreased appetite—Dactinomycin—muscle cancer	0.00184	0.00641	CcSEcCtD
Methazolamide—Dysgeusia—Etoposide—muscle cancer	0.00184	0.00641	CcSEcCtD
Methazolamide—Fatigue—Dactinomycin—muscle cancer	0.00183	0.00636	CcSEcCtD
Methazolamide—Anorexia—Vincristine—muscle cancer	0.00181	0.00628	CcSEcCtD
Methazolamide—Hepatic failure—Doxorubicin—muscle cancer	0.0018	0.00627	CcSEcCtD
Methazolamide—CA5B—tendon—muscle cancer	0.00177	0.0301	CbGeAlD
Methazolamide—Feeling abnormal—Dactinomycin—muscle cancer	0.00175	0.00608	CcSEcCtD
Methazolamide—Ill-defined disorder—Etoposide—muscle cancer	0.00174	0.00607	CcSEcCtD
Methazolamide—CA2—embryo—muscle cancer	0.00172	0.0292	CbGeAlD
Methazolamide—Paraesthesia—Vincristine—muscle cancer	0.0017	0.00592	CcSEcCtD
Methazolamide—Malaise—Etoposide—muscle cancer	0.0017	0.0059	CcSEcCtD
Methazolamide—CA12—head—muscle cancer	0.00169	0.0288	CbGeAlD
Methazolamide—Vertigo—Etoposide—muscle cancer	0.00169	0.00588	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.00168	0.00586	CcSEcCtD
Methazolamide—Leukopenia—Etoposide—muscle cancer	0.00168	0.00586	CcSEcCtD
Methazolamide—Body temperature increased—Dactinomycin—muscle cancer	0.00168	0.00583	CcSEcCtD
Methazolamide—Decreased appetite—Vincristine—muscle cancer	0.00165	0.00573	CcSEcCtD
Methazolamide—CA5B—vagina—muscle cancer	0.00164	0.0279	CbGeAlD
Methazolamide—Gastrointestinal disorder—Vincristine—muscle cancer	0.00164	0.00569	CcSEcCtD
Methazolamide—Fatigue—Vincristine—muscle cancer	0.00163	0.00568	CcSEcCtD
Methazolamide—Convulsion—Etoposide—muscle cancer	0.00163	0.00567	CcSEcCtD
Methazolamide—Discomfort—Etoposide—muscle cancer	0.00158	0.0055	CcSEcCtD
Methazolamide—CA4—renal system—muscle cancer	0.00157	0.0266	CbGeAlD
Methazolamide—Confusional state—Etoposide—muscle cancer	0.00155	0.00539	CcSEcCtD
Methazolamide—Pancytopenia—Methotrexate—muscle cancer	0.00154	0.00534	CcSEcCtD
Methazolamide—Anaphylactic shock—Etoposide—muscle cancer	0.00153	0.00534	CcSEcCtD
Methazolamide—Asthenia—Dactinomycin—muscle cancer	0.00152	0.00529	CcSEcCtD
Methazolamide—CA5B—head—muscle cancer	0.00152	0.0258	CbGeAlD
Methazolamide—CA1—bone marrow—muscle cancer	0.00151	0.0257	CbGeAlD
Methazolamide—Body temperature increased—Vincristine—muscle cancer	0.0015	0.00521	CcSEcCtD
Methazolamide—Photosensitivity reaction—Methotrexate—muscle cancer	0.00148	0.00513	CcSEcCtD
Methazolamide—CA5B—testis—muscle cancer	0.00147	0.0249	CbGeAlD
Methazolamide—Anorexia—Etoposide—muscle cancer	0.00146	0.00509	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.00146	0.00508	CcSEcCtD
Methazolamide—Diarrhoea—Dactinomycin—muscle cancer	0.00145	0.00505	CcSEcCtD
Methazolamide—Drowsiness—Methotrexate—muscle cancer	0.00144	0.00502	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.00143	0.00497	CcSEcCtD
Methazolamide—CA4—cardiac atrium—muscle cancer	0.0014	0.0238	CbGeAlD
Methazolamide—Paraesthesia—Etoposide—muscle cancer	0.00138	0.0048	CcSEcCtD
Methazolamide—Haematuria—Methotrexate—muscle cancer	0.00137	0.00478	CcSEcCtD
Methazolamide—Somnolence—Etoposide—muscle cancer	0.00136	0.00475	CcSEcCtD
Methazolamide—Asthenia—Vincristine—muscle cancer	0.00136	0.00473	CcSEcCtD
Methazolamide—CA2—smooth muscle tissue—muscle cancer	0.00135	0.0229	CbGeAlD
Methazolamide—Vomiting—Dactinomycin—muscle cancer	0.00135	0.00469	CcSEcCtD
Methazolamide—Agranulocytosis—Methotrexate—muscle cancer	0.00135	0.00468	CcSEcCtD
Methazolamide—CA1—head—muscle cancer	0.00134	0.0228	CbGeAlD
Methazolamide—Rash—Dactinomycin—muscle cancer	0.00134	0.00465	CcSEcCtD
Methazolamide—Decreased appetite—Etoposide—muscle cancer	0.00133	0.00464	CcSEcCtD
Methazolamide—Pancytopenia—Doxorubicin—muscle cancer	0.00133	0.00463	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Etoposide—muscle cancer	0.00132	0.00461	CcSEcCtD
Methazolamide—Fatigue—Etoposide—muscle cancer	0.00132	0.0046	CcSEcCtD
Methazolamide—CA2—renal system—muscle cancer	0.0013	0.0221	CbGeAlD
Methazolamide—Diarrhoea—Vincristine—muscle cancer	0.0013	0.00451	CcSEcCtD
Methazolamide—Photosensitivity reaction—Doxorubicin—muscle cancer	0.00128	0.00445	CcSEcCtD
Methazolamide—Feeling abnormal—Etoposide—muscle cancer	0.00126	0.0044	CcSEcCtD
Methazolamide—Nausea—Dactinomycin—muscle cancer	0.00126	0.00438	CcSEcCtD
Methazolamide—Drowsiness—Doxorubicin—muscle cancer	0.00125	0.00434	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.00124	0.00431	CcSEcCtD
Methazolamide—Erythema multiforme—Methotrexate—muscle cancer	0.00122	0.00426	CcSEcCtD
Methazolamide—CA4—tendon—muscle cancer	0.00122	0.0208	CbGeAlD
Methazolamide—Urticaria—Etoposide—muscle cancer	0.00122	0.00424	CcSEcCtD
Methazolamide—Body temperature increased—Etoposide—muscle cancer	0.00121	0.00422	CcSEcCtD
Methazolamide—Tinnitus—Methotrexate—muscle cancer	0.00121	0.0042	CcSEcCtD
Methazolamide—Vomiting—Vincristine—muscle cancer	0.0012	0.00419	CcSEcCtD
Methazolamide—Rash—Vincristine—muscle cancer	0.00119	0.00416	CcSEcCtD
Methazolamide—Dermatitis—Vincristine—muscle cancer	0.00119	0.00415	CcSEcCtD
Methazolamide—Haematuria—Doxorubicin—muscle cancer	0.00119	0.00414	CcSEcCtD
Methazolamide—Headache—Vincristine—muscle cancer	0.00119	0.00413	CcSEcCtD
Methazolamide—CA4—bone marrow—muscle cancer	0.00118	0.0201	CbGeAlD
Methazolamide—Agranulocytosis—Doxorubicin—muscle cancer	0.00116	0.00405	CcSEcCtD
Methazolamide—CA2—cardiac atrium—muscle cancer	0.00116	0.0198	CbGeAlD
Methazolamide—Nausea—Vincristine—muscle cancer	0.00113	0.00392	CcSEcCtD
Methazolamide—Dysgeusia—Methotrexate—muscle cancer	0.0011	0.00384	CcSEcCtD
Methazolamide—Asthenia—Etoposide—muscle cancer	0.0011	0.00383	CcSEcCtD
Methazolamide—Erythema multiforme—Doxorubicin—muscle cancer	0.00106	0.00369	CcSEcCtD
Methazolamide—Diarrhoea—Etoposide—muscle cancer	0.00105	0.00365	CcSEcCtD
Methazolamide—CA4—head—muscle cancer	0.00105	0.0178	CbGeAlD
Methazolamide—Ill-defined disorder—Methotrexate—muscle cancer	0.00105	0.00364	CcSEcCtD
Methazolamide—Tinnitus—Doxorubicin—muscle cancer	0.00104	0.00364	CcSEcCtD
Methazolamide—CYP2E1—renal system—muscle cancer	0.00104	0.0177	CbGeAlD
Methazolamide—CYP2C19—vagina—muscle cancer	0.00103	0.0174	CbGeAlD
Methazolamide—Malaise—Methotrexate—muscle cancer	0.00102	0.00353	CcSEcCtD
Methazolamide—CA2—tendon—muscle cancer	0.00101	0.0172	CbGeAlD
Methazolamide—CA4—testis—muscle cancer	0.00101	0.0172	CbGeAlD
Methazolamide—Vertigo—Methotrexate—muscle cancer	0.00101	0.00352	CcSEcCtD
Methazolamide—Leukopenia—Methotrexate—muscle cancer	0.00101	0.00351	CcSEcCtD
Methazolamide—CA2—bone marrow—muscle cancer	0.000982	0.0167	CbGeAlD
Methazolamide—Convulsion—Methotrexate—muscle cancer	0.000976	0.0034	CcSEcCtD
Methazolamide—Vomiting—Etoposide—muscle cancer	0.000976	0.0034	CcSEcCtD
Methazolamide—Rash—Etoposide—muscle cancer	0.000968	0.00337	CcSEcCtD
Methazolamide—Dermatitis—Etoposide—muscle cancer	0.000967	0.00336	CcSEcCtD
Methazolamide—Headache—Etoposide—muscle cancer	0.000961	0.00335	CcSEcCtD
Methazolamide—Dysgeusia—Doxorubicin—muscle cancer	0.000955	0.00332	CcSEcCtD
Methazolamide—Discomfort—Methotrexate—muscle cancer	0.000947	0.0033	CcSEcCtD
Methazolamide—CA2—vagina—muscle cancer	0.000941	0.016	CbGeAlD
Methazolamide—Confusional state—Methotrexate—muscle cancer	0.000927	0.00323	CcSEcCtD
Methazolamide—Anaphylactic shock—Methotrexate—muscle cancer	0.000919	0.0032	CcSEcCtD
Methazolamide—Nausea—Etoposide—muscle cancer	0.000912	0.00317	CcSEcCtD
Methazolamide—Ill-defined disorder—Doxorubicin—muscle cancer	0.000905	0.00315	CcSEcCtD
Methazolamide—Malaise—Doxorubicin—muscle cancer	0.00088	0.00306	CcSEcCtD
Methazolamide—Vertigo—Doxorubicin—muscle cancer	0.000876	0.00305	CcSEcCtD
Methazolamide—Anorexia—Methotrexate—muscle cancer	0.000876	0.00305	CcSEcCtD
Methazolamide—Leukopenia—Doxorubicin—muscle cancer	0.000873	0.00304	CcSEcCtD
Methazolamide—CA2—head—muscle cancer	0.000869	0.0148	CbGeAlD
Methazolamide—Convulsion—Doxorubicin—muscle cancer	0.000845	0.00294	CcSEcCtD
Methazolamide—CA2—testis—muscle cancer	0.000839	0.0143	CbGeAlD
Methazolamide—CYP3A4—renal system—muscle cancer	0.000838	0.0142	CbGeAlD
Methazolamide—Paraesthesia—Methotrexate—muscle cancer	0.000825	0.00287	CcSEcCtD
Methazolamide—CYP2D6—renal system—muscle cancer	0.000824	0.014	CbGeAlD
Methazolamide—Discomfort—Doxorubicin—muscle cancer	0.00082	0.00286	CcSEcCtD
Methazolamide—Somnolence—Methotrexate—muscle cancer	0.000817	0.00284	CcSEcCtD
Methazolamide—CYP2E1—tendon—muscle cancer	0.000813	0.0138	CbGeAlD
Methazolamide—Dyspepsia—Methotrexate—muscle cancer	0.000809	0.00282	CcSEcCtD
Methazolamide—Confusional state—Doxorubicin—muscle cancer	0.000803	0.00279	CcSEcCtD
Methazolamide—Decreased appetite—Methotrexate—muscle cancer	0.000799	0.00278	CcSEcCtD
Methazolamide—Anaphylactic shock—Doxorubicin—muscle cancer	0.000796	0.00277	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000794	0.00276	CcSEcCtD
Methazolamide—Fatigue—Methotrexate—muscle cancer	0.000793	0.00276	CcSEcCtD
Methazolamide—Anorexia—Doxorubicin—muscle cancer	0.000759	0.00264	CcSEcCtD
Methazolamide—Feeling abnormal—Methotrexate—muscle cancer	0.000758	0.00264	CcSEcCtD
Methazolamide—Urticaria—Methotrexate—muscle cancer	0.00073	0.00254	CcSEcCtD
Methazolamide—Body temperature increased—Methotrexate—muscle cancer	0.000727	0.00253	CcSEcCtD
Methazolamide—Paraesthesia—Doxorubicin—muscle cancer	0.000715	0.00249	CcSEcCtD
Methazolamide—Somnolence—Doxorubicin—muscle cancer	0.000708	0.00246	CcSEcCtD
Methazolamide—Dyspepsia—Doxorubicin—muscle cancer	0.000701	0.00244	CcSEcCtD
Methazolamide—CYP2E1—head—muscle cancer	0.000697	0.0118	CbGeAlD
Methazolamide—Decreased appetite—Doxorubicin—muscle cancer	0.000692	0.00241	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000687	0.00239	CcSEcCtD
Methazolamide—Fatigue—Doxorubicin—muscle cancer	0.000686	0.00239	CcSEcCtD
Methazolamide—CYP2E1—testis—muscle cancer	0.000673	0.0114	CbGeAlD
Methazolamide—Asthenia—Methotrexate—muscle cancer	0.00066	0.0023	CcSEcCtD
Methazolamide—Feeling abnormal—Doxorubicin—muscle cancer	0.000656	0.00228	CcSEcCtD
Methazolamide—Urticaria—Doxorubicin—muscle cancer	0.000632	0.0022	CcSEcCtD
Methazolamide—Body temperature increased—Doxorubicin—muscle cancer	0.000629	0.00219	CcSEcCtD
Methazolamide—Diarrhoea—Methotrexate—muscle cancer	0.000629	0.00219	CcSEcCtD
Methazolamide—Vomiting—Methotrexate—muscle cancer	0.000584	0.00203	CcSEcCtD
Methazolamide—Rash—Methotrexate—muscle cancer	0.00058	0.00202	CcSEcCtD
Methazolamide—Dermatitis—Methotrexate—muscle cancer	0.000579	0.00202	CcSEcCtD
Methazolamide—Headache—Methotrexate—muscle cancer	0.000576	0.002	CcSEcCtD
Methazolamide—Asthenia—Doxorubicin—muscle cancer	0.000571	0.00199	CcSEcCtD
Methazolamide—CYP2D6—head—muscle cancer	0.000552	0.00937	CbGeAlD
Methazolamide—Nausea—Methotrexate—muscle cancer	0.000546	0.0019	CcSEcCtD
Methazolamide—Diarrhoea—Doxorubicin—muscle cancer	0.000545	0.0019	CcSEcCtD
Methazolamide—CYP2D6—testis—muscle cancer	0.000533	0.00905	CbGeAlD
Methazolamide—Vomiting—Doxorubicin—muscle cancer	0.000506	0.00176	CcSEcCtD
Methazolamide—Rash—Doxorubicin—muscle cancer	0.000502	0.00175	CcSEcCtD
Methazolamide—Dermatitis—Doxorubicin—muscle cancer	0.000501	0.00174	CcSEcCtD
Methazolamide—Headache—Doxorubicin—muscle cancer	0.000499	0.00174	CcSEcCtD
Methazolamide—Nausea—Doxorubicin—muscle cancer	0.000473	0.00165	CcSEcCtD
